Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency
Public ClinicalTrials.gov record NCT02207517. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
CITT-ART is a multicenter study (8 locations around the United States) of 324 children ages 9 to \<14 years with symptomatic convergence insufficiency (CI). The purpose of this study is to see if office-based therapy for convergence insufficiency (CI) improves reading ability and attention. CI is an eye-teaming problem where the eyes would like to drift outward when reading or doing close work. When eyes drift out, double vision can happen. To prevent double vision one must use extra effort to keep the eyes from going out. This extra effort can cause symptoms that can interfere with reading and working comfortably at near. These symptoms often include eyestrain, blurred vision, headaches, double vision, and loss of place when reading or performing tasks at near. In a prior study we found that therapy improves these symptoms. In this study we are looking at whether the therapy improves reading and attention
Study identification
- NCT ID
- NCT02207517
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 311 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 9 Years to 13 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2014
- Primary completion
- Jun 30, 2017
- Completion
- Oct 31, 2020
- Last update posted
- Mar 16, 2020
2014 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama, Birmingham College of Optometry | Birmingham | Alabama | 35294 | — |
| Southern California College of Optometry Marshall B. Ketchum University | Fullerton | California | 90037 | — |
| NOVA Southeastern University College of Optometry | Fort Lauderdale | Florida | 33314 | — |
| Bascom Palmer Eye Institute | Miami | Florida | 33136 | — |
| State University of Optometry College of Optometry | New York | New York | 10036 | — |
| Akron Children's Hospital | Akron | Ohio | 44302 | — |
| Ohio State University College of Optometry | Columbus | Ohio | 43210 | — |
| Pennsylvania College of Optometry at Salus University | Philadelphia | Pennsylvania | 19141 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02207517, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2020 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02207517 live on ClinicalTrials.gov.